Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients

Diabetes Care
K MatsumotoY Tominaga

Abstract

To investigate the effects of voglibose, an alpha-glucosidase inhibitor, on daily glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. An open prospective study was conducted in 27 NIDDM patients receiving diet therapy alone or treatment with a sulfonylurea drug. Of the study subjects, 14 patients were treated with voglibose; the remaining 13 patients served as the control group. The metabolic parameters were evaluated before treatment and at week 4 of treatment as follows: glycemic excursions by M-value and 1,5-anhydro-D-glucitol (1,5-AG), insulin secretion by area under the curve of daily serum insulin (AUCinsulin), and insulin sensitivity by the K index of the insulin tolerance test (KITT). After the study treatment, HbA1c and plasma glucose in the patients who had received voglibose were comparable to those of patients in the control group. M-value was lower in the patients treated with voglibose than in the control subjects (5.7 +/- 0.9 vs. 9.8 +/- 1.2, P < 0.05). 1,5-AG was higher in the patients treated with voglibose than in the control subjects (12.2 +/- 1.0 vs. 8.2 +/- 0.7 micrograms/ml, P < 0.01). A statistically significant increase in AUCinsulin occurred after treat...Continue Reading

Citations

Feb 12, 2013·Reviews in Endocrine & Metabolic Disorders·Kieren J Mather
Aug 29, 2000·Diabetes Research and Clinical Practice·T KawasakiY Aiso
Feb 14, 2002·Diabetes Research and Clinical Practice·Apichati VichayanratPraneet Watanakejorn
Apr 25, 2001·Diabetic Medicine : a Journal of the British Diabetic Association·K MatsumotoS Miyake
May 17, 2011·Diabetes, Obesity & Metabolism·A Chaudhuri, P Dandona
Sep 2, 2004·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Shinobu TanakaHiromichi Okuda
Jan 14, 2012·Circulation Journal : Official Journal of the Japanese Circulation Society·Yu KataokaUNKNOWN DIANA study investigators
Nov 7, 2008·The Tohoku Journal of Experimental Medicine·Naoki KohFumio Chino
May 7, 2014·Expert Opinion on Pharmacotherapy·Kohei Kaku
Dec 20, 2007·Expert Review of Molecular Diagnostics·Kathleen M Dungan
Sep 21, 2013·Expert Opinion on Drug Discovery·Maliheh SafaviMohammad Abdollahi
Apr 19, 2003·Diabetes, Obesity & Metabolism·N SekinoT Yamanouchi
May 18, 2004·Journal of Diabetes and Its Complications·Kenji WatanabeRyuzo Kawamori
Jan 20, 2006·Journal of the American Geriatrics Society·Kenzo ObaHiroshi Nakano
Dec 12, 2013·Clinica Chimica Acta; International Journal of Clinical Chemistry·Motoshi OuchiHiroshi Nakano
Jan 7, 2014·Biochemical and Biophysical Research Communications·Hyun Ju DoMin-Jeong Shin
May 16, 2002·Clinical and Experimental Pharmacology & Physiology·Kiyoshi IchikawaMasami Kojima
Jul 24, 2008·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Keiko KorenagaIsao Sakaida
Oct 23, 2003·Endocrine Reviews·Vincenzo De LeoFelice Petraglia
Jan 2, 2001·Endocrine Reviews·S MatthaeiH U Häring
Aug 6, 2000·The Annals of Pharmacotherapy·M S Rendell, W R Kirchain
Nov 15, 2013·Circulation Journal : Official Journal of the Japanese Circulation Society·Takahiro SawadaMitsuhiro Yokoyama

❮ Previous
Next ❯

Related Concepts

Related Feeds

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.